Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: The case of alosetron and its implications

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 8, 2003, Pages 1021-1030

  Ladabaum, U ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON;

ADULT; ANALYTIC METHOD; ARTICLE; CONSTIPATION; DIARRHEA; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTERMETHOD COMPARISON; IRRITABLE COLON; ISCHEMIC COLITIS; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SYMPTOMATOLOGY;

CARBOLINES; COLONIC DISEASES, FUNCTIONAL; COST-BENEFIT ANALYSIS; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SAFETY;

EID: 0038368785     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01545.x     Document Type: Article

References (48)

1. American Gastroenterological Association. Medical position statement: irritable bowel syndrome. Gastroenterology 1997; 112: 2118-9.
2. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-85.
3. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002; 24: 675-89, discussion 4.
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-11.
5. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
6. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 652-68.
7. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
8. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
9. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
10. Letter regarding Lotronex from Dr Janet Woodcock, Director, Center for Drug Evaluation and Research. November 18, 2000: http://www.fda.gov/cder/drug/infopage/lotronex/lotronex ∼consumer letter.htm.
11. Glaxo Wellcome decided to withdraw Lotronex from the market. U.S. Food and Drug Administration: T00-65. November 28, 2000: http://www.fda.gov/bss/topics/ANSWERS/ANS1058.html.
12. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet 2001; 357: 1544-5.
13. Christensen J. The FDA and The Lancet: an exchange. Lancet 2001; 358: 417.
14. Galson S, Kweder S, Houn F, Raczkowski V, Honig PK. The FDA and The Lancet: an exchange. Lancet 2001; 358: 415.
15. Hirschfeld S, Kieffer L, McGuinn WD, Rothmann M, Timmer WC. The FDA and The Lancet: an exchange. Lancet 2001; 358: 415-6.
16. Malozowski S. The FDA and The Lancet: an exchange. Lancet 2001; 358: 416-7.
17. Walker A. The FDA and The Lancet: an exchange. Lancet 2001; 358: 417.
18. Horton R. The FDA and The Lancet: an exchange. Richard Horton's reply. Lancet 2001; 358: 417-8.
19. Lotoronex Information. Center for Drug Evaluation and Research 2002: http://www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc 1996; 276: 1253-8.
21. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3 - Estimating probabilities and utilities. Med Decis Making 1997; 17: 136-41.
22. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results. Med Decis Making 1997; 17: 142-51.
23. Life Tables. In: Vital Statistics of the United States. Preprint of Vol. II, Mortality, Part A. Section 6. Hyattsville, MD: National Center for Health Statistics, 1998.
24. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996: 214-35.
25. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23: 203-35.
26. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
27. Whitehead WE, Burnett CK, Cook EW 3rd, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-53.
28. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997; 17: 1-9.
29. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
30. Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860-8.
31. The DRG Handbook: Comparative Clinical and Financial Standards. Baltimore, MD: HCIA, Inc. and Ernst & Young LLP. 1997.
32. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96: 3122-9.
33. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc., 2001.
34. Medicare. Revised 2000 National Physician Fee Schedule Relative Value File: http://www.hcfa.gov/stats/pufiles.htm.
35. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-27.
36. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001; 135: 769-81.
37. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
38. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993; 148: 927-9.
39. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90.
40. Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making 2000; 20: 72-8.
41. Luscombe FA. Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Qual Life Res 2000; 9: 161-76.
42. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559-75.
43. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
44. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. Prim Care 1995; 22: 271-80.
45. Drummond MF. Experimental versus observational data in the economic evaluation of pharmaceuticals. Med Decis Making 1998; 18: S12-8.
46. PausJenssen AM, Detsky AS. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track? Med Decis Making 1998; 18: S19-22.
47. Lewis C. Grappling with the quality of life. Patients, FDA and drug companies struggle to link therapies with well-being. FDA Consum 2001; 35: 30-5.
48. Camilleri M, Atanasova E, Carlson PJ. et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425-32.